Cargando…

Short-Acting β(2)-Agonist Use Could Be a Confounding Factor for Interpreting Increased IL-6

Detalles Bibliográficos
Autor principal:	Nannini, Luis J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605194/ https://www.ncbi.nlm.nih.gov/pubmed/32687403 http://dx.doi.org/10.1164/rccm.202006-2297LE

Ejemplares similares

It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
por: Nannini, Luis J.
Publicado: (2023)

Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Baraldi, Eugenio, et al.
Publicado: (2022)

Reply to Baraldi and Piacentini: Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Duijts, Liesbeth, et al.
Publicado: (2022)

Confounding by linkage disequilibrium
por: Aissani, Brahim
Publicado: (2014)

Confounding in case control studies
por: Raina, Sunil Kumar
Publicado: (2015)

Mortality in IMPACT: Confounded by Asthma?
por: Suissa, Samy
Publicado: (2020)

The prion dilemma confounding science educators
por: Zaitsev, Igor V, et al.
Publicado: (2013)

Reply: Confounding in Mendelian randomisation studies
por: Reynolds, Carl J., et al.
Publicado: (2023)

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
por: Lipson, David A., et al.
Publicado: (2020)

Oxygen-Free Days and the Confounders of Clinical Practice
por: Lellouche, François, et al.
Publicado: (2022)

Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease
por: Pouwels, Simon D., et al.
Publicado: (2019)

Confounders of uric acid level for assessing cardiovascular outcomes
por: Dogan, Mehmet, et al.
Publicado: (2016)

Chronologic Bias, Confounding by Indication, and COVID-19 Care
por: Keller, Kevin, et al.
Publicado: (2021)

High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality
por: Janson, Christer, et al.
Publicado: (2023)

Tolvaptan, Kidney Function Decline, and Potential Confounding by Muscle Wasting
por: Groothof, Dion, et al.
Publicado: (2023)

Compromised periodontal status could increase mortality for patients with COVID-19
por: Gupta, Shipra, et al.
Publicado: (2022)

Hyperoxemia and Death of the Critically Ill: Is There a Problem of Confounding by Indication or Outcome?
por: Tasker, Robert C.
Publicado: (2020)

Reply to Pouwels et al.: Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease
por: Stockley, Robert A., et al.
Publicado: (2019)

Confounding factors in article stating that Ubiquitin C terminal hydrolase predicts poor neurological outcome after cardiac arrest
por: Honoré, Patrick M., et al.
Publicado: (2023)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

Major Potential Confounder Not Addressed
por: Vines, Jennifer
Publicado: (2006)

Systemic IL-6 and Severe Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

Role of IL-6 in Severe Inflammation
por: Inoue, Ken-ichiro, et al.
Publicado: (2021)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
por: Spek, C. Arnold, et al.
Publicado: (2023)

Magnesium sulphate intravenously reduces tachycardia side-effects of β(2)-agonists
por: Sellers, William F.S., et al.
Publicado: (2022)

Genetic variation may confound analysis of CRISPR-Cas9 off-target mutations
por: Wang, Guanqun, et al.
Publicado: (2018)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

It is time to end our love affair with short-acting β(2)-agonists in asthma
por: Crooks, Michael G., et al.
Publicado: (2022)

Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
por: Bovijn, Jonas, et al.
Publicado: (2021)

Early hyperoxia and 28-day mortality in patients on venoarterial ECMO support for refractory cardiogenic shock: discussion about potential confounding factors
por: Winiszewski, Hadrien, et al.
Publicado: (2022)

COVID-19: Clean up on IL-6
por: Hedrick, Tanner L., et al.
Publicado: (2020)

Reported association of air pollution and suicide rate could be confounded
por: Afshari, R.
Publicado: (2017)

Reply to: Magnesium sulphate intravenously reduces tachycardia side-effects of β(2)-agonists
por: Powell, Colin, et al.
Publicado: (2022)

Role of total lung stress on the progression of early COVID-19 pneumonia: collinearity and potential confounders
por: Neetz, Benjamin, et al.
Publicado: (2021)

Mometasone furoate/formoterol combination therapy increases frequency of days/nights free of short-acting β(2)-agonist use
por: Nayak, AS, et al.
Publicado: (2011)

Uncovering interpretable potential confounders in electronic medical records
por: Zeng, Jiaming, et al.
Publicado: (2022)

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures
por: Figiel, Sandy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_942sne14b24d75r6q2l0j4qk54